前列地尔联合依帕司他治疗糖尿病肾病患者临床疗效分析  

Clinical efficacy of alprostadil combined with ealapril in the treatment of patients with diabetic nephropathy

作　　者：雒华[1] 刘延[1] 贺晓莉[1] LUO Hua;LIU }Tan;HE Xiao-li(The Affiliated Hospital of Yan＇an University,Yan＇an 716000,China)

机构地区：[1]延安大学附属医院,延安716000

出　　处：《内科急危重症杂志》2018年第4期275-277,共3页Journal of Critical Care In Internal Medicine

摘　　要：目的:分析前列地尔联合依帕司他治疗对糖尿病肾病患者氧化应激状态及尿蛋白水平的影响。方法:将674例糖尿病肾病患者按照随机数字表法分为试验组(前列地尔+依帕司他治疗)和对照组(前列地尔治疗),每组387例,比较2组患者治疗前、后丙二醛(MDA)和超氧化物歧化酶(SOD)含量,血清尿素氮(BUN)、肌酐(Scr)、24h尿蛋白(UAE)、糖化血红蛋白(Hb AIC)、空腹血糖(FBG)、血清白蛋白(ALB)含量、总胆固醇(TC)和甘油三酯(TG)水平。结果:试验组的总有效率高于对照组(90. 44%vs 72. 87%,P <0. 05)。试验组治疗后MDA低于治疗前[(4. 6±0. 5) nmol/m L vs (8. 2±0. 8) nmol/m L],SOD高于治疗前[(57. 9±4. 3) U/m L vs (26. 8±3. 5) U/m L],且治疗后,试验组的MDA低于对照组,SOD高于对照组(均P <0. 05)。试验组治疗后BUN、UAE、Scr、FBG、ALB、TG和TC与治疗前比较,差异有统计学意义(均P <0. 05),且治疗后试验组各指标优于对照组(均P <0. 05)。结论:前列地尔联合依帕司他治疗糖尿病肾病,可改善患者氧化应激状态,降低尿蛋白水平。Objective： To analyze the effects of alprostadil combined with epalrestat treatment on the oxidative stress and urinary protein levels in patients with diabetic nephropathy. Methods： 674 patients with diabetic nephropathy were randomly divided into the experimental group（ alprostadil plus epalrestat treatment） and the control group（ alprostadil treatment）,387 cases in each group. The contents of malondialdehyde（ MDA） and superoxide dismutase（ SOD）,blood urea nitrogen（ BUN）,serum creatinine（ Scr）,24-h urine protein（ UAE）,Hb AIC,fasting blood glucose（ FBG）,serum albumin（ ALB）,total cholesterol（ TC）,and triglyceride（ TG） levels were compared before and after treatment in two groups. Results： The total effective rate in the experimental group was significantly higher than that in the control group（ 90. 44% vs72. 87%,P〈0. 05）. In the experimental group after treatment,MDA content was lower [（4.6 ± 0.5）nmol/mL vs（ 8. 2 ±0. 8） nmol/m L] and SOD was higher [（ 57. 9 ± 4.3） U/m L vs（ 26.8±3.5） U/m L] than before treatment. After treatment,the MDA in the experimental group was lower than that in the control group. The SOD content in the experimental group was significantly higher than that in the control group（ P〈0. 05）. In the experimental group,the BUN,UAE,Scr,FBG,ALB,TG and TC after treatment were significantly different from those before treatment（ P〈0. 05）,and after treatment,each index was better than the control group（ P0. 05 for all）. Conclusion： The alprostadil combined with epalrestat in treatment of diabetic nephropathy can improve oxidative stress and reduce urinary protein level.

关 键 词：前列地尔 依帕司他 糖尿病肾病 氧化应激 尿蛋白 

分 类 号：R587.2[医药卫生—内分泌]